Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Pericardial Effusion 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Leukemia 1Inflammatory Breast Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cyclophosphamide 38Paclitaxel 22Epirubicin 21Trastuzumab 20Docetaxel 20Doxorubicin 19Carboplatin 15Radiotherapy 13Taxes 11Filgrastim 11Neoadjuvant Therapy 9Bevacizumab 9Fluorouracil 8pembrolizumab 7Tamoxifen 7Albumin-Bound Paclitaxel 7Capecitabine 6pertuzumab 5Thiotepa 5Peripheral Blood Stem Cell Transplantation 5Lapatinib 5130-nm albumin-bound paclitaxel 5pegfilgrastim 4Granulocyte Colony-Stimulating Factor 4Cisplatin 4Chemotherapy, Adjuvant 4Biopsy 4tipifarnib 3eribulin 3Surgical Procedures, Operative 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Inflammatory Breast Neoplasms × NOV 002 × Clear all
NCT00499122 2018-01-02

NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer

University of Miami

Phase 2 Completed
41 enrolled 10 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡